3 results
Approved WMORecruiting
- Primary study objective: To demonstrate the superiority of the ablative microboost dose schedule regarding 5-year biochemical no evidence of disease rate compared to the current standard of care.- Secondary study objectives: Establish and compareā¦
Approved WMOCompleted
To evaluate and compare progression free survival (PSA) between the two treatment arms.
Approved WMORecruitment stopped
To determine if denosumab is non-inferior to zoledronic acid (Zometa) with respect to the first on-study occurrence of a skeletal-related event (SRE) in men with hormone-refractory prostate cancer and bone metastases.